AstraZeneca PLC ADR (AZN) Social Stream
Featured Post From StockTwits About AZN
$BCRXPitBullTrades, published August 14, 2021
Proyect : BCX9930 ☣
Goal : Become the most valuable asset in the entire bio-sector.
BCX9930 an oral, potent and selective inhibitor of the Factor D enzyme that activates Factor B to form the C3 alternative pathway.
• Can potentially treat 8 diseases. Currently being studied in 4. TAM ranges between $28B ~ $51B
• Ability to treat Intravascular and Extravascular haemolysis.
• Has been granted Fast Track & Orphan drug designation.
• KOL's (KeyOpinionLeaders) praise Ph1 data noting "it can't do any better"
• Best-in-class-inhibitor 👑
Picture below shows the top 10 drug list by worldwide sales in 2020. Understanding how BCX9930 is the best-in-class inhibitor, and its massive TAM ~ $40B, the likelihood of it joinning the top 10 list seems to be really high.
After analyzing BCX9930 and its massive growth potential, we come to the conclusion that BCRX is severely undervalued below $3B MC.
$AZN $JNJ $ABBV $GILD